Shu Liu

机构：Tangshan People's Hospital, Liaoning Provincial People's Hospital · ORCID：0000-0001-6819-1219

发表论文 7 篇 · 总被引 306 次 · h-index 5

代表论文

• Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells (2015 · Oncotarget · 被引 103)
• Design, synthesis and pharmacological evaluation of novel tacrine–caffeic acid hybrids as multi-targeted compounds against Alzheimer’s disease (2012 · Bioorganic & Medicinal Chemistry Letters · 被引 102)
• Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia (2019 · Diabetes Obesity and Metabolism · 被引 53)
• The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region (2019 · Journal of Biological Chemistry · 被引 34)
• Ajmalicine and its Analogues Against AChE and BuChE for the Management of Alzheimer’s Disease: An In-silico Study (2020 · Current Pharmaceutical Design · 被引 14)
• Efficacy and Safety of Bronchoalveolar Lavage in the Treatment ofSevere CAP (2019)